Key result
A portable atrial fibrillation screening device demonstrated 90.2% sensitivity for AF detection compared to 12-lead ECG, and a positive screen was associated with heart disease (OR 3.9, p<0.001).
Why the study?
The study evaluated the performance of a novel handheld dual-electrode portable screening device for atrial fibrillation detection in primary care patients referred for echocardiogram.
Does a portable atrial fibrillation screening device accurately detect AF compared to 12-lead ECG in primary care patients?
Cross-Sectional (n=1,518)
Does a portable atrial fibrillation screening device accurately detect AF compared to 12-lead ECG in primary care patients?
A portable handheld AF screening device demonstrated high sensitivity (90.2%) and specificity (84.0%) for detecting AF in primary care patients, and positive results were associated with structural heart disease.
Supports portable AF screening in primary care; leaves open need for confirmatory ECG given moderate specificity.
INTRODUCTION: A novel handheld dual-electrode stick is a portable atrial fibrillation (AF) screening device (AFSD). We evaluated AFSD performance in primary care patients referred for echocardiogram (echo). METHODS: The AFSD has a light indication of irregular rhythm and single-lead ECG recording. Patients were instructed to hold the device for 1 min, and AF indication was recorded. A 12-lead ECG was performed for all AFSD-positive patients and 250 patients with negative AFSD screen. Echos were performed based on a clinical risk score: all high-risk patients and a sampling of low-risk patients underwent complete echo. Intermediate risk patients first had a screening echocardiogram, with a follow-up complete study if abnormality was suspected. RESULTS: In 5 days, 1518 patients underwent clinical evaluation and cardiovascular risk stratification: mean age 58±16 years, 66% women. The AFSD was positive in 6.4%: 12.6% high risk, 6.1% intermediate risk and 2.2% low risk. Older age was a risk factor (9.3% vs 4.8% in those more than and less than 65 years, p=0.001). AFSD positive was independently associated with heart disease in echo (OR=3.9, 95% CI 2.1 to 7.2, p<0.001). Compared with 12-lead ECG, the AFSD had sensitivity of 90.2% (95% CI 77.0% to 97.3%) and specificity of 84.0% (95% CI 79.3% to 88.0%) for AF detection. CONCLUSION: AFSD demonstrated high sensitivity for AF detection in primary care patients referred for echo. AF prevalence was substantial and independently associated with structural or functional heart disease, suggesting that AFSD screening could be a useful primary care tool to stratify risk and prioritise echo.
No takes yet. Share an insight, caveat, or question.
Diamantino et al. (2020) conducted a cross-sectional in Atrial fibrillation (n=1,518). Portable atrial fibrillation screening device (AFSD) vs. 12-lead ECG was evaluated on Heart disease on echocardiogram (OR 3.9, 95% CI 2.1 to 7.2, p=<0.001). A portable atrial fibrillation screening device demonstrated 90.2% sensitivity for AF detection compared to 12-lead ECG, and a positive screen was associated with heart disease (OR 3.9, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: